Clinical Trials Logo

Advanced Colorectal Cancer clinical trials

View clinical trials related to Advanced Colorectal Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06369259 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Start date: October 31, 2024
Phase: Phase 2
Study type: Interventional

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

NCT ID: NCT05963087 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Start date: August 2023
Phase: N/A
Study type: Interventional

To explore the efficacy and safety of Cetuximab in combination with dabrafenib and Tislelizumab in BRAF mutated treatment of advanced colorectal cancer

NCT ID: NCT05928312 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

Start date: August 28, 2023
Phase: N/A
Study type: Interventional

To explore the efficacy and safety of fruquintinib combined with chemotherapy as third-line/third-line+ Treatment in advanced metastatic colorectal cancer

NCT ID: NCT05364489 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-arm, prospective, open-label observational clinical study to evaluate the efficacy and safety of Bevacizumab combined with Oxaliplatin and TAS-102 in patients with advanced unresectable rectal cancer.

NCT ID: NCT04734249 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Start date: March 2021
Phase: Phase 2
Study type: Interventional

A phase II, muti-cohort study to assess the efficacy and safety of Surufatinib combined with chemotherapy as a second-line treatment in patients with advanced CRC

NCT ID: NCT02923622 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer

Start date: September 2016
Phase: N/A
Study type: Observational

Although patients of colorectal cancer use Traditional Chinese Medicine (TCM) herbal therapy extensively in China, no strong evidence exists to demonstrate the safety and survival outcomes of TCM herbal therapy combined with conventional western medicine for treatment of this disease. The purpose of this multi-center perspective cohort study is to evaluate the relationship between TCM herbal therapy and survival outcomes in patients with advanced colorectal cancer.

NCT ID: NCT02826837 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

LEAC-102 for Advanced Colorectal Cancer

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer